Gliomas
25
5
5
9
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.0%
3 terminated out of 25 trials
75.0%
-11.5% vs benchmark
4%
1 trials in Phase 3/4
44%
4 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (25)
Chronic Convection Enhanced Delivery of Topotecan
Ultralow Dose PET Imaging of 18F-FDOPA
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
Location-Molecular Integrated Outcomes in 450 Cerebellar Glioma Microsurgical Cases
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
AI-assisted Diagnosis of Malignant Brain Tumors
A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)
A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression
Surgical Suction Aspirates Fluorescence Measurement
Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
ZOOMit-fMRI Identifies Motor Functional Cortex
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression